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Vadabte p-Value Odds Ratio 
Post % Stenosis 0.001 1.25 per 10% f 
DCA 0*0006 3.29 
Thrombus 0.0001 10.19 
Major Dissection 0.0001 16.59 
Di~d~el~ Mellitus 0.018 0.72 
Mulltvessel Dtsease 0.029 1.47 
There was no differential effect of Integrelin on the risk factors for AC. 
Consequences of AC including in.hospital and 30 day death, MI, and CABG, 
were unaffected by treatment. In patients requiring emergent CABG, there 
was no excess in bleeding complications: 
Inlegmlin (n = 49) Racebo (n - 37) p-value 
Major ~ to~ 10.5% 24.3% 0.08 
RBC transfusion 63.3'Y,, 75.7% 0.22 
P1stelet transfusion 51.0% 37.8% 0,22 
In conclusion, 1) integrelin significantly reduced the dsk of abrupt closure, 
without a differential effect on dsk factore or sequelae. 2) The bleeding dsk in 
patients requiring emergent CABG was not increased in the Integrefin group. 
~"~ Comparison Between Unfractionated and Hepadn 
Low Molecular Wetght Hepadn During 
Percutaneous Transiuminsl Coronary Angioplasty 
in the 24 Hours After Intervention 
Rooul Bonan, Melitta B. Preisack, Karl R. Karsch, the REDUCE Study 
Group. Montreal Heart Institute, Montreal, Quebec, Canada 
The efle~-I of two different kinds of hepadn, an unfraction~ted (H) and a low 
molecular weight (LMWH), revipadn, was examined in coronary angioplasty 
(PTCA), regarding the level st anticoagulation and immediate results. Six 
hundred and twelve patients were randomized between H and LMWH in the 
setting of the REDUCE trial, Partial thremboplastin time (PTT) was measured 
twice a day following 24,000 U of H over 24 hre of intravenous infusion/twice 
daily placebo s.c. injections in group I (306 pts) and after 10,500 U infusion 
of revipadn followed by twice a day 3,500 U s.c. application of revtpadn in 
group It (308 pts). 
Group t Group II P 
Fr'r (mean sac) 84.4 48,S 0.017 
Myocardial infarction 6 9 0*782 
Death 0 0 - 
Stem implantation 2t 6 0.003 
Autoperfttsion t~ffoone 16 9 0,096 
Herr~t0rr~ 26 12 0*065 
Decrease tn hemoglobin >2 g/dl 62 35 0.002 
Major bleedings 8 7 0*800 
Conclusions: A standard ose of revipadn applied in coronary angioplasty 
is associated with batter immediate results and tess hemorrhagic 0mpfi- 
cations than hepadn. Moreover, this uniform dose of LMWH eliminated the 
need for follow.u,'~ PTi'. 
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• Incomplete Expansion of Coronary Stem: Risk of 
Thromhogenesls end Protection Provided by a 
Hepadn Coating 
John F. Kocsis, Anthony C. Lunn, Syed F. Mohammed 1. Johnson & Johnson 
Interventlonal Systems, Warren, NJ; ~ University of Utah, Salt Lake City, UT 
Palmaz-Sohatz stents, uncoated or with a Carmeda Bioa~tive Surface (CBAS), 
were used to assess the effect of incomplete xpansion and to determine if 
the hapadn coating provided superior thromberesistance in poorly deployed 
slants. Stente were expanded in 3.0 mm polyurethane tubing and subjected 
to 0, 25, or 5~= stenasts using a mechanioal crimping device. Two types of 
restdotions were created: 1) tubing-stent apposition and consffiction, a~d 2) 
constd=lon of the etent with a gap between the tubing and the slant. Constric- 
tions were located either at the midsection of the proximal slant segment, or 
at the proximal end of the stent. The stem-containing tubing was inserted into 
an in vitro test model consisting of a pneumatically.driven ventricle, tdleaflot 
valves and • blood reservoir. Fresh hepadnized bovine blood with autolog0us 
111 ledium-labgled platetats was cimutated at an initial blood flow rate of 100 
4- 20 mVmin through each test conduit, and blood flow was monitored con- 
tinuously. Platalet deposition was quantitated by gamma counting. Results: 
1) Unrestricted stente: the heparin coating reduced platelet deposition by 
91% (p < 0.05); 2) Sfente with 25% restriction: the heparin coating reduced 
plateiot deposition by 68% (p = 0.05); 3) Stente with 50% restriction:the hep- 
arin coating reduced ptatelet deposition by 50% (not s tab ly  significant). 
The CBAS hepadn coating provided protection against platelet deposition in 
fully expanded as well as in incompletely expanded stents, suggesting that 
the hepadn coating may offer added protection in the event that slants are 
not fully expanded when deployed. 
Heparln Coating Dramatically Reduces Platelet 
Deposit ion on ~cempletely Deployed 
Polmaz-Schatz in th~ Baboon A-V Shunt 
Nicolas A.F. Chmnos 2, Keith A. Robinson ;, Deborah White2 Spencer 
B. King III 1, John Koscis 3, Anthony Lunn 3 Andrew Kelly ~, 
Lawrence Harker 2. 3 Johnson and Johnson Intetvenfional Systems/no, 
Warren, NJ; ~ Andreas Gruentzig Cardiovascular Center, Atlanta, GA; 
2 Divis~'on of Hematology of Emery University, Atlanta, GA 
intrsvescular Ultrasound studies have established the s.tgnifioant frequency 
of inadequately deployed intraoorenary stents. To investigate the efficacy of 
a covaiontly bound hepadn [Carmeda ® Bioactive Surface (CBAS)] in reduc- 
ing stent thrombosis despite incomplete deployment, we used the baboon 
exteriorized A-V-shunt model Palmaz-Schatz" PS153 stents were deployed 
in 3.2 mm (i.d.) silicone tubing by 7 elm balloon inflations. A mechanical 
crimping device produced reproducible patterns of stent constriction (25=/0 
and 50% by diameter). Four types of constriction were created: (WA) waft 
apposition to the stem in which the silicone tubing was maintained by a wire 
placed around the silicone tube: (SWG) in which a gap was created between 
the slant and the silicone tube; restrictions were at the proximal end (PER) or 
within the proximal segment (POCR) of the uni*articulated stent. The slanted 
tubing segme=ts were introduced into the non.anticoagulated exte;torized 
A-V shunt and bleed flow was maintained at t 00 ml/min for 2 hours. Platelets 
were prelaboted with m In and fibdnogan with 1251, 
Results: Uncoated slants rapidly recruited platelats and by 90 minutes all 
stanosed slants had occluded. With the heparin coating there was no piotelet 
deposition detestable throughout the tuff 120 minutes of the shunt studies (p 
< 0.0001). Only occasional adherent platelets and microthmmbi were seen 
by scanning etectmn microscopy. 
Uncoated 30 rain 60 rain go rain 
25% SWG, PEfl 0.~-~ .:E 0.08 2.08 ~0~°9 2.34 :b 0.23 
25%WA, POCR 1.70d: 0.63 2.95:E 0.09 occluded 
50% SWG, PER 0.77 d: 0.00 1.59 :E 0.00 occluded 
50% WA, POCR 0.49 ~ 0*00 1.66:1:0*00 OCCluded 
Coaled 30 rain 80 min 90 rain 
25% SWG, PER 0.03 d:0,0t 0.03 4-0.01 0.03±0.01 
25% WA, POCR 0.02 • 0.0 ~, 0*07:1:0.03 0.10 =f= 0.05 
50% SWG, PER 0.00 ±0.00 0.07 :b0.00 0.t6 =t: 0.00 
50% WA, POCR 0.00 *" 0*00 0.02 ± 0.00 0.06 • 0.00 
Discussion: CBAS hepadn coating of the slant eliminated occlusive throm- 
bosis and markedly reduced platalet adhesion in incompletely deployed 
slants. Thus because the heparin coating currently utilized in the Becestent 
I1 study is thrembo-reslstant there is little risk of acute thrombotic closure 
associated with incomplete stem deployment. 
Heparln Coated Polmaz-Schalz" Stents Are Highly 
• Thrombo-Reslstanl: A Baboon A.V Shunt Study 
Nicolas A.R Chrenos 2, Keith A, Robinson 1 Spencer S. King III I, 
Anthony Lunn 3, Deborah White 2, Andrew B. Kelly 2, Laurence A. Herker 2. 
a Johnson and Johnson Intetvantional Systems, Warren, NJ; ~ Andreas 
Gruentzig Cardiovascular Center, Atlanta, GA; 2 Division of Hematology of 
Emery University, Atlanta, GA 
Palmaz-Schatz TM 1 PS153 stents bearing covalently bound hepadn [Carmeda ® 
Bioaciive Surface (CBAS)] are currently being tested in clinical studies in Eu- 
ropa (BENESTENT II). Preliminary animal studies revealed good entithrem- 
botts properties. To further charectedse the hepadn coating and assess the 
maximum: ttithrembotio Potential in reducing stent thrembosLs, we have per- 
formed studies in the baboon exteriorized A,V-shunt model of thrombosis. 
Palmaz-Schatz TM PS153 slants were deployed in 3.2 mm (i.d.) silicone tubing 
using a balloon catheter inflated to 7 atmospheres. The stented tubing seg- 
ments were introduced into the non-anticoagulated exteriorized A-V primate 
shunt and blood flow was maintained at 100 ml/mln for 2 hours. Plalelete 
were pretabaled with 1~1 h~ and flbrinngen with 12Sl. 
